We are live on ! Find out more

Replimune Group

REPL

Market cap $1.24B

13.11 USD

+0.19

1.47%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

13.02

-0.09

0.69%

1 day

1.47%

5 days

-12.01%

1 month

-12.42%

3 months

46.32%

6 months

78.12%

Year to date

47.3%

1 year

131.22%

5 years

-58.09%

10 years

-13.52%

About: Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Employees: 465

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 8.1%

Neutral 88.7%

Negative 3.2%

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

Investors allege Replimune Group, Inc. built its RP1 regulatory strategy around single-arm trial designs the FDA had already questioned, including response criteria the agency said were not consistent with RECIST v1.1 Investors allege Replimune Group, Inc. built its RP1 regulatory strategy around single-arm trial designs the FDA had already questioned, including response criteria the agency said were not consistent with RECIST v1.1

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers.

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

REPL Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against Replimune Group, Inc.

Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1

REPL Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against Replimune Group, Inc.

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - September 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026, both dates inclusive (the "Class Period").

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm

REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Replimune Group, Inc. (NASDAQ: REPL) of a pending securities class action on behalf of purchasers between October 20, 2025 and April 10, 2026. Check if you might be eligible to recover your investment losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.Shares closed at a Class Period high of $10.73 on December 8, 2025 and closed at $1.70 on April 13, 2026, an approximate decline of.

REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers.

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact SueWallSt

Institutional holders of Replimune Group, Inc. (NASDAQ: REPL) may wish to evaluate lead plaintiff options in a securities class action alleging the Company did not disclose that its RP1 trial designs failed to address study-design concerns the FDA had previously communicated. NEW YORK, Sept.

REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact SueWallSt

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - September 9, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026, both dates inclusive (the "Class Period").

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

See News Rankings

Price charts implemented using Lightweight Charts™